Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity.
MIRA Pharmaceuticals, Inc. today announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog.
Milestone Phase II Clinical Study Demonstrates Niagen ® , Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD).
QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.
Evommune, Inc. today announced it has entered into a definitive, worldwide license agreement with AprilBio Co., Ltd. (Kosdaq: 397030), a biopharmaceutical company based in South Korea dedicated to developing specialized biologics and antibody drugs, for an IL-18 targeted fusion protein.
Anixa Biosciences, Inc. today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial.
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial Read More »
Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of a second undisclosed milestone related to the first target under the collaboration.
ILiAD Biotechnologies, LLC today announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
Oncolytics Biotech ® Inc. today announced that Matt Coffey, PhD, President and Chief Executive Officer of Oncolytics will take a medical leave of absence, effective immediately. Wayne Pisano, Chair of Oncolytics’ Board of Directors, will serve as the interim CEO during Dr. Coffey’s absence.
